Clinical Trials Week back issues from September 2008:
PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet.
Sep 01, 2008 ... New phase 2 data published in The Lancet show that the investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 results in statistically significant improvements in the chloride channel function of patients ...
Dyax Announces DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial EDEMA4.
Sep 01, 2008 ... Dyax Corp. (NASDAQ:DYAX) announced positive topline results from its second Phase 3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 (ecallantide) for hereditary angioedema (HAE). The EDEMA4 trial, conducted under a Special Protocol Assessment granted by the U.S ....
Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants.
Sep 01, 2008 ... Vical Incorporated (NASDAQ:VICL) announced that results from nonhuman primate studies of a Vaxfectin(R)-formulated DNA vaccine for measles, published in the August issue of Clinical and Vaccine Immunology(1), offer a promising approach to the development of a measles vaccine to address an ...
Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss.
Sep 01, 2008 ... Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin leads to rapid weight loss and reduced food intake. The ...
New adenocarcinoma research reported from University of Texas.
Sep 01, 2008 ... " We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma. Patients and Methods Eligible patients with pancreatic head/uncinate process ...
Data on DNA research detailed by researchers at University of Arizona.(Report)
Sep 01, 2008 ... According to a study from the United States, "The levels of tobacco-related DNA adducts inhuman tissues reflect a dynamic process that is dependent on the intensity and time of exposure to tobacco smoke, the metabolic balance between activation of detoxification mechanisms, and the removal ...
Data on life sciences described by researchers at Columbia University.
Sep 01, 2008 ... According to recent research published in the International Journal of Stroke, "There is growing experimental and clinical evidence that by reducing downstream products of the mevalonate pathway other than cholesterol, HMG-CoA reductase inhibitors ('statins') have beneficial effects on ...
Study data from Bayer HealthCare update knowledge of pulmonary hypertension.
Sep 01, 2008 ... According to a study from Wuppertal, Germany, "The aim of the study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 63-2521, a new drug in development for pulmonary hypertension. Fifty-eight healthy male volunteers received a single oral dose of BAY ...
Scientists at University of Colorado target schizophrenia.
Sep 01, 2008 ... "Nicotinic acetylcholine receptors are possible therapeutic targets for schizophrenia, as shown by neurobiological and molecular evidence for deficiencies in expression of alpha(7)-nicotinic receptors. Patients' heavy smoking suggests attempted self-medication through this mechanism," ...
Research results from H.J. Aubin and colleagues update understanding of transdermal delivery.
Sep 01, 2008 ... According to a study from Limeil-Brevannes, France, "Varenicline, a new treatment for smoking cessation, has demonstrated significantly greater efficacy over placebo and sustained release bupropion ( bupropion SR). A study was undertaken to compare a 12-week standard regimen of varenicline ...
New atopic dermatitis animal studies research has been reported by scientists at Daejeon University, College of Oriental Medicine.(Report)
Sep 01, 2008 ... New investigation results, 'Blockade of atopic dermatitis-like skin lesions by DA-9102, a natural medicine isolated from Actinidia arguta, in the Mg-deficiency induced dermatitis model of hairless rats,' are detailed in a study published in Experimental Biology and Medicine. "DA-9102 ...
Affymax Reports Second Quarter 2008 Financial Results.(Financial report)
Sep 01, 2008 ... Affymax, Inc. (Nasdaq:AFFY) reported financial results for the second quarter ended June 30, 2008. The net loss for the second quarter of 2008 was $18.9 million compared to a net loss of $9.2 million for the second quarter of 2007 (see also Affymax, Inc.). Affymax recognized ...
AMAG Pharmaceuticals Receives Fast Track Designation for Ferumoxytol for Vascular-Enhanced Magnetic Resonance Imaging.
Sep 01, 2008 ... AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ferumoxytol for its development as a diagnostic agent for Vascular-Enhanced Magnetic Resonance Imaging (VE-MRI) to improve the assessment of peripheral ...
Can-Fite BioPharma: Seikagaku Corporation, the Exclusive Licensee of CF101 in Japan, Is to Commence Phase I Clinical Trial in Japan With CF101 for the Treatment of Rheumatoid Arthritis.
Sep 01, 2008 ... Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange announced that Seikagaku Corporation (SKK), the exclusive licensee of Can-Fite's CF101 in the Japanese market, is about to commence phase I clinical trial in Japan with CF101 for the treatment of ...
Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results.(Financial report)
Sep 01, 2008 ... Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) reported financial results for the second quarter and six months ended June 30, 2008 (see also Catalyst Pharmaceutical Partners, Inc.). "We continue to progress with our clinical development program for CPP-109," stated ...
Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members.
Sep 01, 2008 ... The Association of Clinical Research Organizations (ACRO), which represents the clinical research organization (CRO) industry to regulators, biopharmaceutical clients, policy makers and the public in the U.S. and worldwide, announced the addition of two new member companies to the ...
Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation.
Sep 01, 2008 ... Addrenex Pharmaceuticals ( http://www.addrenex.com/ ) has made three strategic hires this month to further its goal of identifying and developing as many new drug candidates as possible over the next 18 months (see also Clinical Trial Research). The fast-paced timeline they have ...
Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment.
Sep 01, 2008 ... Pharmaxis (NASDAQ:PXSL) announced that the first pivotal Phase 3 clinical trial of Bronchitol for the treatment of cystic fibrosis has completed enrolment (see also Cystic Fibrosis). The first efficacy data from the trial is expected to be available during the first half of ...
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial.
Sep 01, 2008 ... Ardea Biosciences, Inc. (NASDAQ:RDEA) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1 study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the Company's lead product candidate for the treatment of ...
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease.
Sep 01, 2008 ... Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved XENAZINE(R) (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). XENAZINE is the first and only FDA-approved ...
Kamada Successfully Completes Phase II Trial with Aerosolized AAT in Cystic Fibrosis Patients.
Sep 01, 2008 ... Kamada (TASE: KMDA), a bio-pharmaceutical company (www.kamada.com) engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that it has completed a Phase II Study with Aerosolized Alpha-1 Antitrypsin (AAT), delivered via an optimized eFlow ...
Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug.
Sep 01, 2008 ... Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced the successful completion of its Phase 1b randomized controlled multi-dose safety and pharmacokinetics study of ...
RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial.
Sep 01, 2008 ... REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced that it completed enrollment of its first of four ongoing Phase II clinical trials. The trial is a double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of the Company's ...
Advances in Conceptualizing Disease Progression in Alzheimer's Disease.
Sep 01, 2008 ... A hallmark of this year's ICAD meeting was the wealth of new clinical trials information in Alzheimer's Disease (AD). Years of basic and preclinical research have paved the road for development of new medications and biologics. Results from many new clinical trials were provided, ranging ...
Potential diabetes treatment selectively kills autoimmune cells from human patients.
Sep 08, 2008 ... In experiments using blood cells from human patients with diabetes and other autoimmune disorders, Massachusetts General Hospital (MGH) researchers have confirmed the mechanism behind a potential new therapy for type 1 diabetes. A team led by Denise Faustman, MD, PhD, director of the MGH ...
PolyMedix Initiates Dosing in Phase I Clinical Study of Novel Systemic Antibiotic Compound.
Sep 08, 2008 ... PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in Canada for ...
New Publication Shows Cleviprex is Safe and Effective for Treatment of Acute, Severe Hypertension.
Sep 08, 2008 ... The Medicines Company (NASDAQ: MDCO) announced that the results of VELOCITY, a pivotal Phase 3 safety and efficacy trial of its new intravenous (IV) therapy Cleviprex(TM) (clevidipine butyrate) injectable emulsion, were published in the August issue of the Annals of Emergency Medicine. The ...
Research from New York University, Medical Department in angiogenesis provides new insights.
Sep 08, 2008 ... According to recent research from the United States, "Tetrathiomolybdate (TM) is an oral copper-depleting agent that has been shown to inhibit angiogenesis, and angiogenesis is a predictor of poor prognosis in malignant pleural mesothelioma. We hypothesized that cytoreduction of malignant ...
New chronic myelogenous leukemia findings from University of Heidelberg published.
Sep 08, 2008 ... According to recent research from Mannheim, Germany, "Dasatinib, a potent inhibitor of BCR-ABL in vitro, is effective for patients with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. To provide a more definitive assessment of dasatinib in chronic-phase (CP)-CML, we ...
Uppsala University publishes research in Alzheimer disease.(Report)
Sep 08, 2008 ... New research, 'Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial,' is the subject of a report. According to a study from Uppsala, Sweden, "PBT2 is a ...
Study data from Amgen, Inc. provide new insights into gas chromatography.
Sep 08, 2008 ... Researchers detail in 'Determination of residual isobutylene oxide--a genotoxic starting material in a drug substance by static headspace gas chromatography,' new data in gas chromatography. According to a study from the United States, "A sensitive static headspace gas chromatography ...
New findings in multiple sclerosis clinical trial described from Vrije University, Department of Radiology.
Sep 08, 2008 ... Scientists discuss in 'Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis' new findings in multiple sclerosis. "MRI is often used as primary outcome measure in phase II clinical trials in multiple sclerosis (MS). Since persistent T1 hypointense ...
Studies from University of Michigan, Department of Neurology add new findings in the area of multiple sclerosis therapy.(Clinical report)
Sep 08, 2008 ... Researchers detail in 'Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study,' new data in multiple sclerosis. According to ...
Research findings from K.M. Becker et al update understanding of smoking.
Sep 08, 2008 ... Researchers detail in 'A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation,' new data in smoking. "A randomized double-blind, active controlled, parallel group, multi-center phase II clinical trial was conducted to ...
Data on substance withdrawal syndrome therapy discussed by researchers at University of Pennsylvania.
Sep 08, 2008 ... Scientists discuss in 'A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal' new findings in substance withdrawal syndrome. According to a study from the United States, "Lofexidine is an alpha-2-adrenergic ...
Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: the Journal of Arthroscopic and Related Surgery.(Financial report)
Sep 08, 2008 ... Omeros Corporation announced the publication of the results from a Phase 1/Phase 2 trial investigating OMS103HP in arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is ...
MDS Pharma Services Strengthens Medical Leadership in Phase IIa Clinical Research.
Sep 08, 2008 ... MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has hired Ross Tonkens, MD, to provide medical oversight for its Phase IIa clinical research activities and to direct the medical and clinical activities of its Development & Regulatory Services ...
After Their U.S. Purchase, Algorithme Pharma Gains a Foothold in Europe Through the Acquisition of a New Clinical Research Location in the United Kingdom.
Sep 08, 2008 ... The Laval-based firm Algorithme Pharma is pleased to announce that it has achieved its goal of securing a European facility through its acquisition of Simbec Research Ltd in Merthyr Tydfil, Wales. This news comes only six weeks after confirming the purchase of another clinical research ...
Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial.
Sep 08, 2008 ... Human Genome Sciences, Inc. (NASDAQ:HGSI) announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B(R) (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being ...
Isolagen Reports Positive Results from Open Label, Phase II Study of Isolagen Therapy(TM) of the Full Face Regarding the Treatment of Wrinkles and Skin Quality Characteristics.(Clinical report)
Sep 08, 2008 ... Isolagen(TM), Inc. (AMEX:ILE) announced results from a prospective, open label, Phase II study (IT-R-007) of Isolagen Therapy(TM) for the treatment of facial wrinkles and creases in approximately 40 subjects. Study subjects received two treatments of Isolagen Therapy in multiple facial ...
Memory Pharmaceuticals Closes Final Tranche of Equity Financing with the Stanley Medical Research Institute.
Sep 08, 2008 ... Memory Pharmaceuticals Corp. (NASDAQ:MEMY) announced that it has secured $2.0 million through the sale of approximately 4.7 million shares of common stock at $0.42 per share under its June 2007 equity financing agreement with an investment group led by The Stanley Medical Research ...
Eric Karran, CSO of the Neurodegenerative Diseases Drug Hunting Team at Eli Lilly & Co. to Give Keynote Presentation at GTCbios 4th Neurodegenerative Diseases Drug Discovery Conference in Philadelphia, PA.(Conference news)
Sep 08, 2008 ... Dr. Eric Karran, Chief Scientific Officer of the Neurodegenerative Diseases Drug Hunting Team at Eli Lilly & Company will give the keynote address entitled "Progress with LY450139, a Functional Gamma Secretase Inhibitor in Phase 3 Trials for Alzheimer's Disease" at the 4th ...
Pharmos Corporation Announces That it Will Cease Operations in Israel.
Sep 08, 2008 ... Pharmos Corporation (NASDAQ:PARS) announced that effective October 31, 2008 it will cease operations in Rehovot, Israel, and manage those activities currently based in Rehovot out of the Company's US headquarters in Iselin, New Jersey (see also Pharmos Corporation). The research ...
Neurotech Granted Fast Track Designations from the FDA for NT-501 in Two Indications - Retinitis Pigmentosa and Dry Age-Related Macular Degeneration.
Sep 15, 2008 ... Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for NT-501 for the treatment of ...
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma.(Clinical report)
Sep 15, 2008 ... Human Genome Sciences, Inc. (NASDAQ:HGSI) reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. The initial data from the ...
BioCryst Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis.(Financial report)(Clinical report)
Sep 15, 2008 ... BioCryst Pharmaceuticals (NASDAQ:BCRX) announced results from the completed Phase IIa trial of BCX-4208 in patients with moderate to severe plaque psoriasis. Consistent with interim findings reported in May 2008, this study of BCX-4208, a potent, rationally designed, orally available ...
Regeneron's ARCALYST rilonacept Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy.(Clinical report)
Sep 15, 2008 ... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that treatment with ARCALYST(R) (rilonacept), also known as IL-1 Trap, in a Phase 2 study of gout patients initiating therapy with allopurinol to lower their uric acid levels, produced a statistically significant reduction versus ...
Targanta Therapeutics Announces Positive Top-Line Results from Oritavancin Phase 2 SIMPLIFI Trial.(Financial report)
Sep 15, 2008 ... Targanta Therapeutics Corporation (Nasdaq: TARG) announced positive top-line results from a Phase 2 clinical trial investigating the efficacy and safety of oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI ....
Studies from University of California in the area of Alzheimer disease described.
Sep 15, 2008 ... In this recent report published in the journal Archives of Neurology, researchers in the United States conducted a study "To evaluate the safety, tolerability, and amyloid beta (A beta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease. Multicenter, randomized, ...
New clinical trial research study findings have been reported from University of Nottingham.(Clinical report)
Sep 15, 2008 ... According to a study from Nottingham, the United Kingdom, "Information sheets for clinical research are becoming increasingly complex but the extent to which they are understood is uncertain. To assess, as our primary outcome, recall by healthy volunteers of key facts in a patient ...
Research from J.M. Berlin et al has provided new information about surgery.(Clinical report)
Sep 15, 2008 ... According to a study from the United States, "Actinic keratoses are increasingly common skin lesions that are evaluated and treated by dermatologists on a daily basis. It is estimated that more than 90% of actinic keratoses in the US are treated by destructive therapies, such as ...
Reports from Karolinska Institut, Department of Medicine add new data to research in enzyme research.(Report)
Sep 15, 2008 ... Research findings, 'PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes,' are discussed in a new report. According to recent research published in the journal Toxicology and Applied Pharmacology, "In this work, we investigated ...
New findings reported from Ohio State University, College of Public Health describe advances in life sciences.(Report)
Sep 15, 2008 ... A report, 'An evaluation of the Italian version of the Fagerstrom Test for Nicotine Dependence,' is newly published data in Psychological Reports. "This study examined the psychometric properties of an Italian version of the Fagerstrom Test for Nicotine Dependence in a sample of 593 ...
Aeris Therapeutics Announces Phase 2 Trial Results for Non-Surgical Emphysema Treatment.
Sep 15, 2008 ... Aeris Therapeutics, Inc. (www.aerist.com), a company specializing in the development and commercialization of novel treatments for patients with emphysema and other advanced lung diseases, announced that the primary efficacy endpoint in Phase 2 clinical trials for its Biologic Lung Volume ...
Pfizer and Medivation Enter Into Global Agreement To Co-develop and Market Dimebon for the Treatment of Alzheimers and Huntingtons Diseases.
Sep 15, 2008 ... Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an ...
Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth.
Sep 15, 2008 ... Calabar AB, a privately held pharmaceutical company developing therapies for treating dry mouth, announced a EUR 350,000 equity financing from the investment company Karolinska Development AB. The financing will take Calabar's product through a phase II study with repeated dosing. "We ...
Oncothyreon announces prioritization plan for development programs.
Sep 15, 2008 ... Oncothyreon Inc. (NASDAQ:ONTY) (TSX: ONY) (the "Company") announced a prioritization plan to focus the Company's resources on the clinical development of PX-478 and PX-866 and on process development and manufacturing of Stimuvax(R). Oncothyreon will seek a partner for further clinical ...
Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections.
Sep 15, 2008 ... Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered ...
Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins.
Sep 15, 2008 ... Pharmaceutical company Pharmaxis (NASDAQ:PXSL) announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers (see also Cystic Fibrosis). The Phase 3 trial is being conducted in 41 hospitals ...
DiaKine Therapeutics Announces Financing and New Board Member.
Sep 15, 2008 ... DiaKine Therapeutics, developers of drugs designed to cause diabetes to go into remission, announced that BlueTree Allied Angels has invested in the company. Additionally, J. James Frost M.D., Ph.D., M.B.A, has been elected as BlueTree's representative on DiaKine's Board of Directors (see ...
QUATRx Initiates Second Phase 3 Study of OPHENA (Ospemifene Tablets) in Women with Postmenopausal Vaginal Syndrome.
Sep 15, 2008 ... QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, announced that it has initiated a second Phase 3 clinical trial of OphenaO (ospemifene tablets), the ...
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis.
Sep 15, 2008 ... Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The PETAL ...
Helix Electric Completes Electrical Contracting Project for Carlsbad Ranch Resort Center.
Sep 15, 2008 ... Helix Electric, one of the largest open shop electrical contractors in the nation, has completed an electrical contracting project for the Carlsbad Ranch Resort Center, Phase I (see also Helix Electric). Located on 15 acres at the crossroads of Carlsbad's tourism and business ...
Idera Pharmaceuticals Announces Milestone Payment Under Asthma and Allergy Collaboration.
Sep 15, 2008 ... Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), announced that it will receive a milestone payment from Novartis under the two companies' research collaboration and license agreements. Under the terms of the agreement, the payment was triggered by the initiation of a Phase 1 clinical study by ...
Dutton Associates Announces Investment Opinion: NexMed Lowered To Speculative Buy Rating In Research Note By Dutton Associates.
Sep 15, 2008 ... Dutton Associates updates its coverage of NexMed (Nasdaq:NEXM), lowering its rating to Speculative Buy and a $1.00 price target. The research note by Dutton senior analyst Denise Resnik, MS is available at www.jmdutton.com as well as from First Call, Bloomberg, FactSet, Capital IQ, Zacks, ...